Shandong Boan Biotechnology Co Ltd (HKSE:06955) Share Price

Company Profile

Business description
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
Contact
No. 39 Keji Avenue
High-Tech Industrial Development Zone
Shandong Province
Yantai
CHN
T: +86 5354379111
https://www.boan-bio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
696

Recommended

International expansion is a distraction from valuable local business.

Roy Van Keulen | 14 May 2026

The chipmaker’s IPO priced at $185, well above its initial range, and opened trading at an eye-popping $350.

Jacob Robbins | 14 May 2026

How the most traded shares in April stack up against our analysts views.

Tyger Fitzpatrick | 14 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,788.10	30.40	-0.34%
CAC 40	7,952.55	129.72	-1.61%
DAX 40	23,950.57	505.69	-2.07%
Dow JONES (US)	49,526.17	537.29	-1.07%
FTSE 100	10,195.37	177.56	-1.71%
HKSE	25,962.73	426.31	-1.62%
NASDAQ	26,225.14	410.08	-1.54%
Nikkei 225	61,120.33	288.96	-0.47%
NZX 50 Index	12,875.24	89.77	-0.69%
S&P 500	7,408.50	92.74	-1.24%
S&P/ASX 200	8,552.50	25.40	-0.30%
SSE Composite Index	4,135.39	42.53	-1.02%